摘要
原发性膜性肾病(primary membranous nephropathy,PMN)是成人原发性肾病综合征的主要原因,近年来在国内发病率逐年增加。随着抗磷脂酶A2受体(PLA2R)抗体和抗I型血小板域蛋白7A(THSD7A)抗体的发现,我们对PMN发病机制的认识也取得重要的进展。本文将从膜性肾病的认识历程、PLA2R的临床应用价值、免疫抑制治疗的时机、免疫抑制治疗方案方面对PMN的诊治进展进行综述。
Primary membranous nephropathy(PMN)is the most common cause of primary nephrotic syndrome in adults.The prevalence of PMN in China was significantly increased during the past decade.The identification of autoantibodies against phospholipidase A2 receptor(PLA2 R)and thrombospondin type-1 domain-containing 7 A(THSD7 A)is helpful in the understanding and treatment of PMN.This review focuses on the clinical significance of PLA2 R,the time and regimens of immunosuppressive therapy in PMN.
作者
谢琼虹(综述)
陈瑞颖
薛骏
郝传明(审校)
XIE Qiong-hong;CHEN Rui-ying;XUE Jun;HAO Chuan-ming(Department of Nephrology,Huashan Hospital,Fudan University,Shanghai 200040,China)
出处
《复旦学报（医学版）》
CAS
CSCD
北大核心
2020年第4期615-621,共7页
Fudan University Journal of Medical Sciences
基金
国家自然科学基金(81670697)。
